CT:HSM Helius Medical Technologies Inc. Class A

Helius Medical Technologies, Inc., a medical technology company, focuses on the development of products for the treatment of neurological symptoms caused by disease or trauma. The company develops, licenses, or acquires noninvasive platform technologies that amplify the brain's ability to heal itself. It is developing portable neuromodulation stimulator or PoNS, device for the treatment of movement, gait, and balance disorders in patients with traumatic brain injury, and other chronic neurological diseases. Helius Medical Technologies, Inc. has a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command for the development of the PoNS treatment for chronic balance deficits related to mild-to moderate traumatic brain injury. The company is headquartered in Newtown, Pennsylvania.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol HSDT.

18.35 CAD
As of 09/09/2021


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  Canada
Country of incorporation:  USA
IPO date:  01/01/1900
Stock exchange:    Toronto Stock Exchange
Exchange country:   Canada
Market cap:   42,531,080 CAD
Current dividend yield:   0.00%
CUSIP:    
ISIN:        US42328V5049
Sedol:      BDT72Z1

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy